U.S. Patent 11,752,103: Tramadol Oral Solution Claims, Exclusivity, and Generic-Entry Risk

U.S. Patent No. 11,752,103 protects a specific 5 mg/mL tramadol hydrochloride aqueous oral solution containing glycerin, propylene glycol, water, and a pH-control buffer. The patent also covers selected excipients, exclusions from the formulation, 24-month stability performance, and treatment of pain using the claimed solution. The patent issued on August 29, 2023, and has a reported expiration date of September 11, 2040, subject to any applicable patent-term adjustment or regulatory extensions.[1][2]

The patent is commercially relevant to Qdolo, an FDA-approved tramadol hydrochloride oral solution marketed by Athena Bioscience, LLC.[3] It is a small-molecule product patent, not a biologic patent. Generic competitors would generally use the ANDA pathway and face formulation, method-of-use, and Orange Book certification risks rather than biosimilar litigation.

What product does U.S. Patent 11,752,103 protect?

The independent product claim protects an aqueous oral solution with five required elements:

Claim element	Required scope
Active ingredient	Tramadol hydrochloride as the sole active ingredient
Tramadol concentration	About 4.5 to 5.5 mg/mL
Glycerin	About 10% to 30% w/v
Propylene glycol	Required by claim 1, but no numerical range in claim 1
Water	Required
Buffer	Sufficient quantity to maintain pH at about 4.5 to 5.5

Claim 1 is the principal composition claim. A competing product that contains a different active ingredient, a second active ingredient, no glycerin, no propylene glycol, a materially different tramadol concentration, or a pH outside the claimed range may avoid literal infringement of claim 1.

The use of "about" creates numerical boundary questions. Courts generally interpret "about" in light of the specification, analytical precision, formulation practice, and prosecution history. A formulation at 5.6 mg/mL or pH 5.6 is not automatically outside the claim. The infringement analysis would depend on the patent record and the technical meaning established during prosecution.

How do the dependent claims narrow the protected formulation?

The dependent claims create multiple fall-back positions around the core composition.

Propylene glycol limitations

Claims 2 and 3 narrow the propylene glycol content:

Claim	Propylene glycol range
Claim 1	Required, amount unspecified
Claim 2	About 4% to 10% w/v
Claim 3	About 5% to 7% w/v

A formulation containing 5% to 7% w/v propylene glycol would fall within claim 3 if it also satisfies all limitations of claim 1. Claim 1 remains broader because it does not state a concentration range for propylene glycol.

Optional excipients

Claim 4 adds sucralose. Claim 5 adds a flavoring agent. Claim 6 adds sodium benzoate, with claim 7 narrowing the preservative concentration to 0.1% to 1% w/v.

These claims are commercially important because an ANDA applicant could attempt to omit sucralose, flavoring, or sodium benzoate. Omitting those ingredients would not avoid claim 1 if the base formulation remains within claim 1, but it could avoid the relevant dependent claim.

Negative formulation limitations

Claims 8 through 10 exclude excipient categories. They are directed to formulations that are free or substantially free of particular ingredients.

Claim 8 excludes polyethylene glycol.

Claim 9 excludes nonionic surfactants and co-solvents.

Claim 10 excludes a broader group that includes:

Sugars
Parabens
Castor oil
Ethanol
Polyethylene glycol
Povidone
Copovidone
Sorbitan monolaurate
Mint oil
Aniseed flavor
Saccharin and its salts
Sodium cyclamate
Polyoxyl 40 hydrogenated castor oil

These limitations can make the patent more difficult to design around if the commercial product depends on a simple, sugar-free and ethanol-free oral solution. They also provide potential infringement positions against products that copy the claimed excipient architecture while changing only a flavor or sweetener.

What does claim 11 add to the patent scope?

Claim 11 requires the solution to retain a tramadol hydrochloride concentration of 0.45% to 0.55% w/v after storage for 24 months at:

25 ± 2°C
40 ± 5% relative humidity

This is a stability-performance limitation. The claim is not satisfied merely because a product initially contains approximately 5 mg/mL tramadol. The product must also satisfy the stated concentration condition after the specified storage period.

The claim raises several proof issues:

The challenger or patent owner would need validated assay data.
The storage protocol must correspond to the claimed temperature and humidity conditions.
The phrase "after storage" may require evidence that the tested batch remained within the concentration range at the end of the period.
The claim does not expressly recite limits for degradation products, appearance, microbial quality, pH drift, or preservative content.

Claim 11 may be harder to establish through routine product testing than claims 1 through 10 because the relevant result depends on time-dependent stability data. It may also be vulnerable to a non-infringement position if a generic product uses a different excipient system and has materially different stability behavior.

What method of treatment is covered by claim 12?

Claim 12 covers treating pain by administering an effective amount of the aqueous oral solution of claim 1.

The claim incorporates every limitation of claim 1. It is not a broad claim to treating pain with tramadol generally. The administered product must be the claimed aqueous solution.

Because pain treatment is the principal labeled use for Qdolo, claim 12 may create a method-of-use issue for an ANDA applicant seeking approval for the same indication. A generic applicant could attempt a section viii labeling carve-out only if the patented use can be omitted from the proposed label without removing the conditions of approval. That strategy is less effective where the patented method tracks the product's principal or sole approved indication.[4]

What is the Orange Book status of U.S. Patent 11,752,103?

FDA Orange Book records identify U.S. Patent 11,752,103 in connection with Qdolo, tramadol hydrochloride oral solution, NDA 214123.[2][3]

Regulatory item	Status
Product	Qdolo
Active ingredient	Tramadol hydrochloride
Dosage form	Oral solution
Strength	5 mg/mL
NDA	214123
FDA approval	June 30, 2023
Patent	U.S. 11,752,103
Patent issue date	August 29, 2023
Reported patent expiration	September 11, 2040
FDA pathway for generics	ANDA, section 505(j)

The patent is a listed drug patent rather than a biologic patent. An ANDA applicant would typically need to submit a Paragraph I, II, III, or IV certification. A Paragraph IV certification would assert that the patent is invalid, unenforceable, or will not be infringed by the proposed generic product.[5]

The patent listing does not itself establish that a Paragraph IV notice has been served or that litigation has been filed. Patent litigation must be evaluated from the ANDA notice, district-court docket, and FDA approval records.

When does tramadol oral solution lose exclusivity?

Patent-based protection is expected to extend to September 11, 2040, based on the reported Orange Book expiration date.[2] That date is separate from FDA regulatory exclusivity.

Tramadol is an established active ingredient. Qdolo therefore does not receive the five-year new chemical entity exclusivity available to an entirely new active moiety. A new dosage form or formulation may qualify for three-year exclusivity when supported by qualifying clinical investigations, but the relevant FDA exclusivity code and expiration date must be distinguished from the patent term.[4]

The practical entry timeline depends on four events:

ANDA submission and certification.
Paragraph IV notice to the patent holder and NDA holder.
Filing of patent litigation within the statutory period.
Resolution of litigation or expiration of the listed patent.

A timely patent infringement action can trigger a 30-month FDA approval stay under the Hatch-Waxman framework, subject to statutory exceptions and court developments.[5]

How strong is the patent estate for Qdolo and tramadol oral solution?

The patent estate appears concentrated rather than broad. The identified patent is strong against an exact or near-exact copy of the commercial 5 mg/mL formulation but does not cover every tramadol oral liquid.

Strengths

The independent claim combines active concentration, glycerin, propylene glycol, water, and pH.
The concentration range maps closely to the commercial 5 mg/mL product.
Claims 8 through 10 protect a defined excipient-exclusion profile.
Claim 11 adds a 24-month stability requirement that may reflect formulation development work.
Claim 12 links the composition to treatment of pain.
The patent expiration date is materially later than the 2023 FDA approval date.

Weaknesses and design-around opportunities

Tramadol hydrochloride is an old active ingredient.
Glycerin, propylene glycol, buffers, sweeteners, preservatives, and flavoring agents are conventional pharmaceutical excipients.
The claim does not cover a defined buffer species or concentration.
The claim does not require a particular container, closure, manufacturing process, or packaging system.
A competitor could evaluate a concentration outside 4.5 to 5.5 mg/mL.
A competitor could replace glycerin, replace propylene glycol, or use a nonaqueous or semi-solid dosage form.
A competitor could develop a different oral liquid with a different pH and stability strategy.
The patent does not claim tramadol polymorphs, particle size, API synthesis, or a controlled-release platform.

The main validity pressure would likely involve obviousness based on prior tramadol oral liquids and conventional excipient combinations. The patent holder's strongest response would be evidence of unexpected stability, palatability, preservative performance, reduced excipient burden, or a technical problem not solved by earlier formulations.

What prior-art and competitive patent issues matter?

The relevant prior-art field includes:

Earlier tramadol hydrochloride oral solutions
Tramadol tablets, capsules, drops, and elixirs
Oral liquid excipient systems using glycerin and propylene glycol
pH-controlled aqueous opioid formulations
Preserved oral solutions using sodium benzoate
Sugar-free pediatric or geriatric oral liquids
Formulation patents directed to stability and palatability

The patent's novelty is unlikely to rest on tramadol alone. Its commercial value depends on the combination of concentration, excipient selection, pH, excluded ingredients, and stability.

A generic applicant has several potential design-around paths:

Design-around strategy	Main risk
Use tramadol concentration outside 4.5-5.5 mg/mL	Dosing equivalence and labeling risk
Omit glycerin	May avoid claim 1, but may affect viscosity and taste
Replace propylene glycol	May alter solubility and stability
Use a different pH range	May create stability or palatability problems
Use ethanol or polyethylene glycol	May avoid claims 8-10 but introduce regulatory and tolerability issues
Use a different preservative	May avoid claims 6-7
Use tablets, capsules, or another dosage form	Avoids the oral-solution claims but does not compete as an equivalent product

What Paragraph IV challenges and litigation risks exist?

A Paragraph IV challenger would likely focus on three issues.

Obviousness

The challenger could argue that a skilled formulator would have selected tramadol hydrochloride, glycerin, propylene glycol, water, and a mildly acidic buffer from known options. The strength of this argument depends on whether the patent record shows predictable formulation development or an unexpected stability result.

Claim construction

The terms "about," "substantially free," "sufficient amount," and "sole active ingredient" create claim-construction issues. The parties would likely dispute:

The numerical boundaries of the tramadol and excipient ranges
Whether trace amounts count as "substantially free"
Whether a formulation containing an inactive opioid-related impurity violates "sole active ingredient"
The scope of "buffer"
Whether claim 11 requires a complete 24-month stability study for infringement

Infringement by equivalent formulation

A product outside the literal ranges could still raise a doctrine-of-equivalents dispute. That risk is reduced where prosecution history shows that the applicant narrowed the ranges to obtain allowance or distinguished prior art using the specific numerical boundaries.

Does biosimilar risk apply to this patent?

No. Biosimilars apply to biological products. Tramadol hydrochloride oral solution is a small-molecule drug. The relevant competitive pathway is an ANDA under section 505(j), not a biosimilar application under section 351(k).

The competitive threat is therefore likely to come from generic manufacturers with liquid-dose manufacturing, analytical testing, stability, and controlled-substance capabilities. Tramadol is a Schedule IV controlled substance in the United States, adding manufacturing, distribution, quota, security, and recordkeeping requirements.[6]

How does the patent compare with broader tramadol protection?

U.S. Patent 11,752,103 is narrower than a patent covering tramadol generally, but it is more commercially targeted.

Protection type	Covered by U.S. 11,752,103?
Tramadol active ingredient generally	No
Tramadol hydrochloride oral solution	Yes, subject to claim limits
5 mg/mL formulation	Yes, within the claimed range
Tablets or capsules	No
Extended-release tramadol	No
API synthesis	No
Polymorph or salt selection	Not expressly
Manufacturing process	No
Pain treatment with any tramadol product	No
Pain treatment with the claimed oral solution	Yes

The patent is therefore a formulation and method-of-use asset. Its value is highest against a directly substitutable 5 mg/mL oral solution and lower against alternative dosage forms or substantially redesigned liquids.

What is the commercial exposure from generic entry?

The commercial exposure depends on whether Qdolo remains the only widely available 5 mg/mL tramadol oral solution and whether the product has meaningful use among patients who cannot swallow tablets or require liquid dose adjustment.

Generic entry could affect:

Net price and reimbursement
Pharmacy substitution
Hospital and institutional contracts
Pediatric, geriatric, and swallowing-disorder markets
Controlled-substance distribution channels
Prescriber preference for a ready-to-use liquid

The patent provides a long nominal exclusivity runway, but the practical barrier is formulation-specific. A technically compliant alternative liquid could create competition before 2040 if it avoids the listed claims and obtains FDA approval.

Key Takeaways

U.S. Patent 11,752,103 protects a narrowly defined aqueous tramadol hydrochloride oral solution.
The core product range is approximately 4.5 to 5.5 mg/mL tramadol hydrochloride, with 10% to 30% w/v glycerin, propylene glycol, water, and a pH of approximately 4.5 to 5.5.
Claims 2 and 3 narrow propylene glycol to 4% to 10% and 5% to 7% w/v.
Claims 8 through 10 protect a formulation substantially free of specified solvents, surfactants, preservatives, sweeteners, flavors, and other excipients.
Claim 11 adds 24-month stability performance.
Claim 12 covers treatment of pain using the claimed solution.
The patent is listed for Qdolo and has a reported expiration date of September 11, 2040.
Generic manufacturers would use the ANDA pathway and may face Paragraph IV, formulation-infringement, and method-of-use issues.
Biosimilar analysis is not applicable.
The principal design-around routes are changing the active concentration, glycerin, propylene glycol, pH, excipient system, or dosage form.
Patent strength is highest against an exact Qdolo-like formulation and lower against a materially different oral liquid.

FAQs About U.S. Patent 11,752,103

What drug is associated with U.S. Patent 11,752,103?

The patent is associated with tramadol hydrochloride oral solution, including Qdolo, a 5 mg/mL product approved by FDA under NDA 214123.

Does U.S. Patent 11,752,103 cover tramadol tablets?

No. The claims require an aqueous oral solution. Tramadol tablets, capsules, and extended-release products are outside the literal scope of the stated claims.

Can a generic use a different flavor and avoid the patent?

Not necessarily. Changing the flavor may avoid claim 5 if the formulation lacks a flavoring agent, but it would not avoid claim 1 if all core composition limitations remain present.

Can a generic avoid the patent by removing sodium benzoate?

Removing sodium benzoate may avoid claims 6 and 7. It would not avoid claim 1 unless the revised product also falls outside one or more limitations of the independent composition claim.

Is the patent a new chemical entity patent?

No. The patent is directed to a formulation and treatment method for tramadol hydrochloride, an established active ingredient. It does not claim tramadol as a new chemical entity.

References

United States Patent and Trademark Office. (2023). U.S. Patent No. 11,752,103, tramadol hydrochloride oral solution.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2023, June 30). Qdolo prescribing information and approval materials, NDA 214123.
U.S. Food and Drug Administration. (2017). Small business assistance: Frequently asked questions for the generic drug user fee amendments.
21 U.S.C. § 355(j); 21 C.F.R. § 314.94.
U.S. Drug Enforcement Administration. (n.d.). Controlled substance schedules.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rosemount	QDOLO	tramadol hydrochloride	SOLUTION;ORAL	214044-001	Sep 1, 2020		DISCN	Yes	No	11,752,103	⤷ Start Trial	Y			MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2021092406	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,752,103

Which drugs does patent 11,752,103 protect, and when does it expire?

Summary for Patent: 11,752,103